- JP-listed companies
- Balance sheet
(E27038) Balance sheet
Market cap
P/E ratio
UMN Pharma develops innovative vaccines for infectious diseases like norovirus and rotavirus while providing contract manufacturing services for biopharmaceuticals.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | |
| Cash and cash equivalents | - | 3,769 | 4,016 | 1,882 | 739 | 566 | 1,734 | 1,018 |
| Total current assets | - | 4,403 | 5,482 | 2,178 | 882 | 650 | 1,837 | 1,077 |
| Property, plant and equipment, net | - | 462 | 440 | 414 | 390 | - | - | 81 |
| Marketable securities, non-current | - | 144 | - | - | - | - | - | - |
| Total non-current assets | - | 1,676 | 2,011 | 4,854 | 5,392 | 44 | 54 | 100 |
| Total assets | - | 6,079 | 7,493 | 7,032 | 6,274 | 694 | 1,891 | 1,177 |
| Short-term debt | - | - | 1,100 | 600 | 3,600 | 6,000 | - | - |
| Long-term debt, current | - | 50 | 75 | 75 | 75 | 25 | - | - |
| Total current liabilities | - | 198 | 1,280 | 258 | 173 | 122 | 47 | 53 |
| Long-term debt, non-current | - | 250 | 175 | 100 | 25 | 4,141 | - | - |
| Total non-current liabilities | - | 611 | 542 | 466 | 393 | 363 | 1,487 | 742 |
| Total liabilities | - | 810 | 1,822 | 724 | 566 | 486 | 1,534 | 795 |
| Common stock and paid-in capital | - | 9,974 | 13,582 | 17,046 | 17,065 | 19,903 | 614 | 1,359 |
| Retained earnings | - | -4,709 | -7,916 | -10,739 | -11,356 | -19,700 | -256 | -985 |
| Stockholders' equity | 2,695 | 5,270 | 5,672 | 6,307 | 5,709 | 209 | 357 | 382 |